Skip to main content
JCO Global Oncology logoLink to JCO Global Oncology
. 2022 May 5;8(Suppl 1):40. doi: 10.1200/GO.22.46000

Health System Costs of a Breast Cancer Early Diagnosis Program in a Rural District of Rwanda

Rashidah Nambaziira 1, Lysa Carolle Niteka 1, Jean Marie Vianney Dusengimana 2, John Ruhumuriza 2, Kayleigh Bhangdia 3, Jean Claude Mugunga 4, Marie Louise Uwineza 5, Vestine Rugema 5, Parsa Erfani 6, Cyprien Shyirambere 2, Lawrence N Shulman 7, Melany Rabideau 1, Lydia E Pace 8
PMCID: PMC9906543

PURPOSE

Low-and-middle-income countries require information about effective and pragmatic strategies to facilitate earlier breast cancer diagnoses. A Breast Cancer Early Detection (BCED) program training health workers and establishing breast clinics in Burera District, Rwanda was associated with increased evaluation of breast symptoms and higher incidence of early-stage breast cancer. We examined the program's cost from the health system perspective.

METHODS

The BCED program's first phase started in 2015 and included seven health centers (HCs) and Butaro Cancer Center of Excellence (BCCOE), the cancer referral center at Butaro Hospital. Patient volume and diagnoses from 2015 to 2017 were abstracted from existing databases. We retrospectively reviewed administrative data to identify start-up and ongoing operational costs. Using Time-Driven Activity-Based Costing, clinical costs per patient visit were estimated based on HC and BCCOE visits for breast health care observed in 2021.

RESULTS

Over the first 2 years, there were 1,010 HC visits for breast symptoms, 210 referrals to BCCOE, and 10 breast cancers diagnosed. The BCED program's total cost was $119,511, comprising of start-up costs ($36,917), recurring operational costs ($67,711) and clinical costs ($14,883). Clinical breast assessment (CBA) at HCs cost $3.27/visit. At BCCOE, CBA-only visits cost $13.47, CBA/ultrasound cost $14.79, and CBA/ultrasound/biopsy cost $147.81. Overall, the clinical cost per breast cancer diagnosed was $1,488. The primary cost drivers were personnel at HCs (55%) and biopsy supplies at BCCOE (46%). In other districts, patients must go to their local HC and district hospital before referral to BCCOE, adding about $14.00/patient.

CONCLUSION

The BCED program's cost at HCs was modest, similar to other outpatient HC services. Hospital-level care was more expensive and requiring multiple visits for biopsies increased costs. Start-up and operational costs could be reduced by using local trainers and virtual/mobile mentorship. For scalability in other districts, decentralizing ultrasound and/or biopsies to district hospitals could reduce costs.

Cyprien Shyirambere

Research Funding: Yes, Bristol Myers Squibb

Melany Rabideau

Employment: yes, Optum

Consulting or Advisory Role: yes, Optum

Travel, Accommodations, Expenses: yes, Optum

Lydia E. Pace

Stock and Other Ownership Interests: Yes, Firefly Health

Research Funding: Yes, Bristol Myers Squibb

No other potential conflicts of interest were reported.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Cyprien Shyirambere

Research Funding: Yes, Bristol Myers Squibb

Melany Rabideau

Employment: yes, Optum

Consulting or Advisory Role: yes, Optum

Travel, Accommodations, Expenses: yes, Optum

Lydia E. Pace

Stock and Other Ownership Interests: Yes, Firefly Health

Research Funding: Yes, Bristol Myers Squibb

No other potential conflicts of interest were reported.


Articles from JCO Global Oncology are provided here courtesy of American Society of Clinical Oncology

RESOURCES